所有图片(1)

文件

安全信息

安全和法规

1435003

USP

甲基强的松龙

Name: 甲基强的松龙
Brand: USP

United States Pharmacopeia (USP) Reference Standard

登录查看公司和协议定价

所有图片(1)

别名:

6α-甲基泼尼松龙, 11β,17α,21-三羟基-6α-甲基-1,4-孕甾二烯-3,20-二酮, 6α-甲基-11β,17α,21-三羟基-1,4-孕甾二烯-3,20-二酮, 甲基强的松龙, 甲基泼尼松龙

经验公式（希尔记法）:

C₂₂H₃₀O₅

CAS号:

83-43-2

分子量:

374.47

Beilstein:

2340300

MDL编号:

MFCD00010591

PubChem化学物质编号:

329750457

等级

pharmaceutical primary standard

API类

methylprednisolone

制造商/商品名称

USP

应用

pharmaceutical (small molecule)

格式

neat

SMILES字符串

[H][C@@]12C[C@H](C)C3=CC(=O)C=C[C@]3(C)[C@@]1([H])[C@@H](O)C[C@@]4(C)[C@@]2([H])CC[C@]4(O)C(=O)CO

InChI

1S/C22H30O5/c1-12-8-14-15-5-7-22(27,18(26)11-23)21(15,3)10-17(25)19(14)20(2)6-4-13(24)9-16(12)20/h4,6,9,12,14-15,17,19,23,25,27H,5,7-8,10-11H2,1-3H3/t12-,14-,15-,17-,19+,20-,21-,22-/m0/s1

InChI key

VHRSUDSXCMQTMA-PJHHCJLFSA-N

基因信息

human ... NR3C1(2908)

正在寻找类似产品? Visit 产品对比指南

一般描述

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

应用

Methylprednisolone USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia.

分析说明

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.

其他说明

Sales restrictions may apply.

警示用语：

Danger

危险声明

H360FD - H373

预防措施声明

P201 - P202 - P260 - P280 - P308 + P313 - P405

危险分类

Repr. 1B - STOT RE 2

储存分类代码

6.1C - Combustible, acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

WGK

WGK 2

法规信息

监管及禁止进口产品

分析证书(COA)

输入产品批号来搜索分析证书(COA) 。批号可以在产品标签上"批“ （Lot或Batch）字后找到。

已有该产品？

为方便起见，与您过往购买产品相关的文件已保存在文档库中。

访问文档库

难以找到您所需的产品或批次号码？

如何查找产品货号

在网站页面上，产品编号会附带包装尺寸/数量一起显示（例如：T1503-25G）。请确保在“产品编号”字段中仅输入产品编号 (示例: T1503).

示例

T1503

货号

25G

包装规格/数量

其它示例：

705578-5MG-PW

PL860-CGA/SHF-1EA

MMYOMAG-74K-13

1000309185

输入内容 1.000309185)

遇到问题？欢迎随时联系我们技术服务寻求帮助

如何查找COA批号

批号可以在产品标签上"批“ （Lot或Batch）字后面找到。

Aldrich 产品

如果您查询到的批号为 TO09019TO 等，请输入去除前两位字母的批号：09019TO。
如果您查询到的批号含有填充代码（例如05427ES-021），请输入去除填充代码-021的批号：05427ES。
如果您查询到的批号含有填充代码（例如 STBB0728K9），请输入去除填充代码K9的批号：STBB0728。

未找到您寻找的产品？

部分情况下，可能未在线提供COA。如果搜索不到COA，可在线索取。

索取COA

Outcomes associated with corticosteroid dosage in critically ill patients with acute exacerbations of chronic obstructive pulmonary disease.

Tyree H Kiser et al.

American journal of respiratory and critical care medicine, 189(9), 1052-1064 (2014-03-13)

Studies evaluating corticosteroid (CS) dosing for patients hospitalized with an acute exacerbation of chronic obstructive pulmonary disease (AECOPD) have largely excluded patients admitted directly to the intensive care unit (ICU), and none have evaluated the effect of CS dosing regimens

Efficacy of methylprednisolone on pain, fatigue, and appetite loss in patients with advanced cancer using opioids: a randomized, placebo-controlled, double-blind trial.

Ornulf Paulsen et al.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 32(29), 3221-3228 (2014-07-09)

Corticosteroids are frequently used in cancer pain management despite limited evidence. This study compares the analgesic efficacy of corticosteroid therapy with placebo. Adult patients with cancer receiving opioids with average pain intensity ≥ 4 (numeric rating scale [NRS], 0 to

Rationale and design of the steroids in cardiac surgery trial.

Richard Whitlock et al.

American heart journal, 167(5), 660-665 (2014-04-29)

Steroids may improve outcomes in high-risk patients undergoing cardiac surgery with the use of cardiopulmonary bypass (CBP). There is a need\ for a large randomized controlled trial to clarify the effect of steroids in such patients. We plan to randomize

Postpartum relapses increase the risk of disability progression in multiple sclerosis: the role of disease modifying drugs.

Emilio Portaccio et al.

Journal of neurology, neurosurgery, and psychiatry, 85(8), 845-850 (2014-01-10)

To assess relapses, disability progression and the role of disease modifying drugs (DMDs) in the year after delivery in women with multiple sclerosis (MS). We prospectively followed-up pregnancies occurring between 2002 and 2008 in women with MS, recruited from 21

Nanoparticle-mediated local delivery of Methylprednisolone after spinal cord injury.

Young-tae Kim et al.

Biomaterials, 30(13), 2582-2590 (2009-02-03)

Systemic administration of a high-dose of Methylprednisolone (MP) can reduce neurological deficits after acute spinal cord injury (SCI). However, the use of high-dose MP in treating acute SCI is controversial due to significant dose related side effects and relatively modest

查看所有相关文献

我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门

文件

安全信息

甲基强的松龙

United States Pharmacopeia (USP) Reference Standard

属性

等级

API类

制造商/商品名称

应用

格式

SMILES字符串

InChI

InChI key

基因信息

相关类别

说明

一般描述

应用

分析说明

其他说明

相关产品

相关产品

安全信息

象形图

警示用语：

危险声明

预防措施声明

危险分类

储存分类代码

WGK

法规信息

文件

分析证书(COA)

已有该产品？

难以找到您所需的产品或批次号码？

Aldrich 产品

未找到您寻找的产品？

同行评审论文

技术服务